• LAST PRICE
    12.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    10.9800/ 1
  • Ask / Lots
    21.0000/ 10
  • Open / Previous Close
    0.0000 / 12.0000
  • Day Range
    ---
  • 52 Week Range
    Low 8.0000
    High 36.2700
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 12.38
TimeVolumeRANI
09:32 ET84412.35
09:48 ET70012.23
10:10 ET10812.25
10:42 ET10012.15
11:08 ET13012.205
11:38 ET20012.35
12:03 ET3169312.75
12:05 ET29812.68
12:14 ET503712.44
12:52 ET20012.46
12:54 ET20012.35
12:56 ET40012.34
12:59 ET10012.34
01:32 ET26512.35
02:33 ET50012.349
03:43 ET58612.44
03:45 ET236312.39
03:52 ET151112
03:54 ET10012.105
03:56 ET20012.105
03:57 ET130012.39
03:59 ET654912
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRANI
Rani Therapeutics Holdings Inc
589.9M
-66.7x
---
United StatesDYN
Dyne Therapeutics Inc
590.9M
-3.7x
---
United StatesJANX
Janux Therapeutics Inc
576.2M
-9.1x
---
United StatesKNTE
Kinnate Biopharma Inc
579.6M
-5.8x
---
United StatesTCDA
Tricida Inc
601.9M
-3.8x
---
United StatesAVTE
Aerovate Therapeutics Inc
610.3M
-18.9x
---
As of 2022-08-08

Company Information

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The Company manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

Contact Information

Headquarters
2051 Ringwood AvenueSAN JOSE, CA, United States 95131
Phone
408-457-3700
Fax
302-655-5049

Executives

Executive Chairman of the Board
Mir Imran
Chief Executive Officer, Director
Talat Imran
Chief Financial Officer
Svai Sanford
Chief Scientific Officer
Mir Hashim
General Counsel
Eric Groen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$589.9M
Revenue (TTM)
$2.0M
Shares Outstanding
49.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.18
Book Value
$0.97
P/E Ratio
-66.7x
Price/Sales (TTM)
300.8
Price/Cash Flow (TTM)
---
Operating Margin
-3,104.59%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.